Does lidocaine attenuate lipopolysaccharide-induced acute lung injury through inhibiting NF-kappaB activation?
Lidocaine attenuates LPS-induced lung injury via mechanisms involving inhibiting NF-kappaB activation and cytokine release, which implies that lidocaine may be a potential anti-inflammatory agent in endotoxemia.
Decreased serum adropin levels are associated with the presence of AMI in CAD patients. These results revealed that adropin might represent as a novel biomarker for predicting AMI onset in CAD patients.